S K PHARM LIMITED

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—4

Registered number: 08845148

		2026		2025
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		6,951		8,689

			6,951		8,689
CURRENT ASSETS
Debtors	5	-		10,000
Cash at bank and in hand		26,879		20,110

		26,879		30,110
Creditors: Amounts Falling Due Within One Year	6	(10,121 )		(11,753 )

NET CURRENT ASSETS (LIABILITIES)			16,758		18,357

TOTAL ASSETS LESS CURRENT LIABILITIES			23,709		27,046

PROVISIONS FOR LIABILITIES
Deferred Taxation			(121 )		(121 )

NET ASSETS			23,588		26,925

CAPITAL AND RESERVES
Called up share capital	7		100		100
Profit and Loss Account			23,488		26,825

SHAREHOLDERS' FUNDS			23,588		26,925

Page 1

Page 2

S K PHARM LIMITED

Balance Sheet (continued)

As At 31 January 2026

For the year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Miss Sonia Kakkar

Director

14/09/2026

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

S K PHARM LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 08845148 . The registered office is 1 Agincourt Villas, Uxbridge Road, Hillingdon, Middlesex, UB10 0NX.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Motor Vehicles	20% on reducing balance
Computer Equipment	20% on reducing balance

3. Average Number of Employees

Average number of employees, including directors, during the year was: NIL (2025: NIL)

4. Tangible Assets

	Motor Vehicles	Computer Equipment	Total
	£	£	£
Cost
As at 1 February 2025	13,250	1,455	14,705

As at 31 January 2026	13,250	1,455	14,705

Depreciation
As at 1 February 2025	4,770	1,246	6,016
Provided during the period	1,696	42	1,738

As at 31 January 2026	6,466	1,288	7,754

Net Book Value
As at 31 January 2026	6,784	167	6,951

As at 1 February 2025	8,480	209	8,689

5. Debtors

	2026	2025
	£	£
Due within one year
Other debtors	-	10,000

6. Creditors: Amounts Falling Due Within One Year

	2026	2025
	£	£
Other creditors	9,271	10,897
Taxation and social security	850	856

	10,121	11,753

Page 3

Page 4

S K PHARM LIMITED

Notes to the Financial Statements (continued)

For The Year Ended 31 January 2026

7. Share Capital

	2026	2025
	£	£
Allotted, Called up and fully paid	100	100

8. Directors Advances, Credits and Guarantees

Included within Creditors are the following loans from directors:

	As at 1 February 2025	Amounts advanced	Amounts repaid	Amounts written off	As at 31 January 2026
	£	£	£	£	£
Miss Sonia Kakkar	10,147	-	2,676	-	7,472

The above loan is unsecured, interest free and repayable on demand.